Literature DB >> 8328914

DNA replication of parvovirus B 19 in a human erythroid leukemia cell line (JK-1) in vitro.

T Takahashi1, K Ozawa, K Takahashi, Y Okuno, T Takahashi1, Y Muto, F Takaku, S Asano.   

Abstract

A major limitation of studies on the parvovirus B 19, a causative agent of transient aplastic crisis, has been the absence of appropriate cell lines permissive for the virus. In the present study, a human erythroid leukemia cell line (JK-1) was shown to support B 19 virus DNA replication in vitro. Forty-eight hours after virus inoculation of JK-1 liquid cell cultures, the average number of B 19 genome copies was estimated at 3,000 per cell by DNA dot blot analysis. The addition of erythropoietin increased B 19 copy number to 10,000 per cell. The presence of replicative forms of the B 19 virus genome was genome was demonstrated by Southern blot analysis. Although persistent infection of B 19 virus was not observed in JK-1 cells, this culture system will be of value in elucidating the molecular basis of the erythroid specificity of parvovirus B 19.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328914     DOI: 10.1007/bf01379092

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  22 in total

1.  Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia.

Authors:  G J Kurtzman; B Cohen; P Meyers; A Amunullah; N S Young
Journal:  Lancet       Date:  1988-11-19       Impact factor: 79.321

2.  Replication and cytopathology of human parvovirus B19 in human umbilical cord blood erythroid progenitor cells.

Authors:  C E Sosa; J B Mahony; K E Luinstra; M Sternbach; M A Chernesky
Journal:  J Med Virol       Date:  1992-02       Impact factor: 2.327

3.  Human parvovirus, the cause of erythema infectiosum (fifth disease)?

Authors:  M J Anderson; S E Jones; S P Fisher-Hoch; E Lewis; S M Hall; C L Bartlett; B J Cohen; P P Mortimer; M S Pereira
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

4.  Parvovirus infections and hypoplastic crisis in sickle-cell anaemia.

Authors:  J R Pattison; S E Jones; J Hodgson; L R Davis; J M White; C E Stroud; L Murtaza
Journal:  Lancet       Date:  1981-03-21       Impact factor: 79.321

5.  Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation.

Authors:  T Takahashi; K Ozawa; K Takahashi; S Asano; F Takaku
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

6.  Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia.

Authors:  U M Saarinen; T L Chorba; P Tattersall; N S Young; L J Anderson; E Palmer; P F Coccia
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

7.  In vitro propagation of parvovirus B19 in primary foetal liver culture.

Authors:  K E Brown; J Mori; B J Cohen; A M Field
Journal:  J Gen Virol       Date:  1991-03       Impact factor: 3.891

8.  Replication of the B19 parvovirus in human bone marrow cell cultures.

Authors:  K Ozawa; G Kurtzman; N Young
Journal:  Science       Date:  1986-08-22       Impact factor: 47.728

9.  Human parvovirus arthropathy.

Authors:  D G White; A D Woolf; P P Mortimer; B J Cohen; D R Blake; P A Bacon
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

10.  Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver.

Authors:  N Yaegashi; H Shiraishi; T Takeshita; M Nakamura; A Yajima; K Sugamura
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

View more
  10 in total

Review 1.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

2.  Human B19 erythrovirus in vitro replication: what's new?

Authors:  Sylvie Pillet; Serge Fichelson; Frédéric Morinet; Neal S Young; Ning Zhi; Susan Wong
Journal:  J Virol       Date:  2008-09       Impact factor: 5.103

3.  Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation.

Authors:  Mikael Sundin; Anna Lindblom; Claes Örvell; A John Barrett; Berit Sundberg; Emma Watz; Agneta Wikman; Kristina Broliden; Katarina Le Blanc
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

4.  Cis-vaccenic acid induces differentiation and up-regulates gamma globin synthesis in K562, JK1 and transgenic mice erythroid progenitor stem cells.

Authors:  Idowu A Aimola; Hajiya M Inuwa; Andrew J Nok; Aisha I Mamman; James J Bieker
Journal:  Eur J Pharmacol       Date:  2016-02-12       Impact factor: 4.432

5.  Human parvovirus B19: a mechanistic overview of infection and DNA replication.

Authors:  Yong Luo; Jianming Qiu
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

Review 6.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

7.  Roles of E4orf6 and VA I RNA in adenovirus-mediated stimulation of human parvovirus B19 DNA replication and structural gene expression.

Authors:  Kerstin Winter; Kristina von Kietzell; Regine Heilbronn; Tanja Pozzuto; Henry Fechner; Stefan Weger
Journal:  J Virol       Date:  2012-02-22       Impact factor: 5.103

8.  Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication.

Authors:  Susan Wong; Ning Zhi; Claudia Filippone; Keyvan Keyvanfar; Sachiko Kajigaya; Kevin E Brown; Neal S Young
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

Review 9.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

Review 10.  Recent Advances in Replication and Infection of Human Parvovirus B19.

Authors:  Safder S Ganaie; Jianming Qiu
Journal:  Front Cell Infect Microbiol       Date:  2018-06-05       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.